Annual report
3154.TEDINET S100UFQT
Period2023-07-01 → 2024-06-30
Filed2024-09-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Amended by S100Z02N (2026-09-03).
Key figures · 158
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥259.8bn | 2023-07-01 → 2024-06-30 | Cons. | Net sales |
| Revenue | ¥239.1bn | 2022-07-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥226.6bn | 2021-07-01 → 2022-06-30d | Cons. | Net sales (5-year summary) |
| Revenue | ¥213.3bn | 2020-07-01 → 2021-06-30d | Cons. | Net sales (5-year summary) |
| Revenue | ¥210.4bn | 2019-07-01 → 2020-06-30d | Cons. | Net sales (5-year summary) |
| Operating income | ¥1.3bn | 2023-07-01 → 2024-06-30 | Cons. | Operating income |
| Operating income | ¥1.9bn | 2022-07-01 → 2023-06-30 | Cons. | Operating income |
| Ordinary income | ¥1.8bn | 2023-07-01 → 2024-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥2.4bn | 2022-07-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥2.8bn | 2021-07-01 → 2022-06-30d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.2bn | 2020-07-01 → 2021-06-30d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.6bn | 2019-07-01 → 2020-06-30d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.9bn | 2023-07-01 → 2024-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥2.5bn | 2022-07-01 → 2023-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.1bn | 2023-07-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.5bn | 2022-07-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.9bn | 2021-07-01 → 2022-06-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.1bn | 2020-07-01 → 2021-06-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥951m | 2019-07-01 → 2020-06-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥1.1bn | 2023-07-01 → 2024-06-30 | Cons. | Profit loss |
| Net income | ¥1.5bn | 2022-07-01 → 2023-06-30 | Cons. | Profit loss |
| Total assets | ¥114.8bn | at 2024-06-30 | Cons. | Assets |
| Total assets | ¥97.5bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥93.0bn | at 2022-06-30d | Cons. | Total assets (5-year summary) |
| Total assets | ¥84.5bn | at 2021-06-30d | Cons. | Total assets (5-year summary) |
| Total assets | ¥70.0bn | at 2020-06-30d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥95.1bn | at 2024-06-30 | Cons. | Liabilities |
| Total liabilities | ¥78.9bn | at 2023-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥19.7bn | at 2024-06-30 | Cons. | Net assets |
| Net assets / equity | ¥18.6bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥17.3bn | at 2022-06-30d | Cons. | Net assets |
| Net assets / equity | ¥15.8bn | at 2021-06-30d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥13.9bn | at 2020-06-30d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥13.6bn | at 2024-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.3bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥13.5bn | at 2024-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.3bn | at 2023-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.1bn | at 2022-06-30d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥12.6bn | at 2021-06-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥8.5bn | at 2020-06-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥1.9bn | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.2bn | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥3.9bn | 2021-07-01 → 2022-06-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥6.8bn | 2020-07-01 → 2021-06-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.2bn | 2019-07-01 → 2020-06-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.7bn | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥863m | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥4.8bn | 2021-07-01 → 2022-06-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥4.6bn | 2020-07-01 → 2021-06-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥138m | 2019-07-01 → 2020-06-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥4.0bn | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥863m | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥5.2bn | 2021-07-01 → 2022-06-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.9bn | 2020-07-01 → 2021-06-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥788m | 2019-07-01 → 2020-06-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥51.21 | 2023-07-01 → 2024-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.32 | 2022-07-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.3 | 2021-07-01 → 2022-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥94.81 | 2020-07-01 → 2021-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥43.66 | 2019-07-01 → 2020-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥51 | 2023-07-01 → 2024-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥68.09 | 2022-07-01 → 2023-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥85.15 | 2021-07-01 → 2022-06-30d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥94.15 | 2020-07-01 → 2021-06-30d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥43.6 | 2019-07-01 → 2020-06-30d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥891.21 | at 2024-06-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥847.1 | at 2023-06-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥789.43 | at 2022-06-30d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥727.12 | at 2021-06-30d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥636.71 | at 2020-06-30d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 17.2% | at 2024-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.1% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 18.6% | at 2022-06-30d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 18.8% | at 2021-06-30d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.8% | at 2020-06-30d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 5.9% | 2023-07-01 → 2024-06-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.4% | 2022-07-01 → 2023-06-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 11.3% | 2021-07-01 → 2022-06-30d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 13.9% | 2020-07-01 → 2021-06-30d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.2% | 2019-07-01 → 2020-06-30d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 2,517 | at 2024-06-30 | Cons. | Number of employees |
| Employees | 2,288 | at 2023-06-30 | Cons. | Number of employees |
| Employees | 2,182 | at 2022-06-30d | Cons. | Number of employees |
| Employees | 2,002 | at 2021-06-30d | Cons. | Number of employees |
| Employees | 1,926 | at 2020-06-30d | Cons. | Number of employees |
| Revenue | ¥2.9bn | 2023-07-01 → 2024-06-30 | Standalone | Net sales |
| Revenue | ¥3.0bn | 2022-07-01 → 2023-06-30 | Standalone | Net sales |
| Revenue | ¥2.7bn | 2021-07-01 → 2022-06-30d | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.4bn | 2020-07-01 → 2021-06-30d | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.2bn | 2019-07-01 → 2020-06-30d | Standalone | Net sales (5-year summary) |
| Operating income | ¥458m | 2023-07-01 → 2024-06-30 | Standalone | Operating income |
| Operating income | ¥743m | 2022-07-01 → 2023-06-30 | Standalone | Operating income |
| Ordinary income | ¥707m | 2023-07-01 → 2024-06-30 | Standalone | Ordinary income |
| Ordinary income | ¥968m | 2022-07-01 → 2023-06-30 | Standalone | Ordinary income |
| Ordinary income | ¥998m | 2021-07-01 → 2022-06-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥703m | 2020-07-01 → 2021-06-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥486m | 2019-07-01 → 2020-06-30d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥707m | 2023-07-01 → 2024-06-30 | Standalone | Income before income taxes |
| Profit before tax | ¥1.1bn | 2022-07-01 → 2023-06-30 | Standalone | Income before income taxes |
| Net income | ¥649m | 2023-07-01 → 2024-06-30 | Standalone | Profit loss |
| Net income | ¥1.0bn | 2022-07-01 → 2023-06-30 | Standalone | Profit loss |
| Net income | ¥932m | 2021-07-01 → 2022-06-30d | Standalone | Net income loss (5-year summary) |
| Net income | ¥663m | 2020-07-01 → 2021-06-30d | Standalone | Net income loss (5-year summary) |
| Net income | ¥853m | 2019-07-01 → 2020-06-30d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥26.0bn | at 2024-06-30 | Standalone | Assets |
| Total assets | ¥22.8bn | at 2023-06-30 | Standalone | Assets |
| Total assets | ¥23.9bn | at 2022-06-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥21.5bn | at 2021-06-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥21.5bn | at 2020-06-30d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥16.1bn | at 2024-06-30 | Standalone | Liabilities |
| Total liabilities | ¥13.5bn | at 2023-06-30 | Standalone | Liabilities |
| Net assets / equity | ¥9.9bn | at 2024-06-30 | Standalone | Net assets |
| Net assets / equity | ¥9.3bn | at 2023-06-30 | Standalone | Net assets |
| Net assets / equity | ¥8.6bn | at 2022-06-30d | Standalone | Net assets |
| Net assets / equity | ¥8.1bn | at 2021-06-30d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥7.6bn | at 2020-06-30d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥192m | at 2024-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥298m | at 2023-06-30 | Standalone | Cash and deposits |
| EPS (basic) | ¥29.55 | 2023-07-01 → 2024-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.27 | 2022-07-01 → 2023-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥42.56 | 2021-07-01 → 2022-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.43 | 2020-07-01 → 2021-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥39.16 | 2019-07-01 → 2020-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥29.43 | 2023-07-01 → 2024-06-30 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥46.12 | 2022-07-01 → 2023-06-30 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥42.48 | 2021-07-01 → 2022-06-30d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥30.22 | 2020-07-01 → 2021-06-30d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥39.12 | 2019-07-01 → 2020-06-30d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥21 | 2023-07-01 → 2024-06-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥22 | 2022-07-01 → 2023-06-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥19 | 2021-07-01 → 2022-06-30d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥21 | 2020-07-01 → 2021-06-30d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2019-07-01 → 2020-06-30d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥448.09 | at 2024-06-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥425.81 | at 2023-06-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥394.52 | at 2022-06-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥372.32 | at 2021-06-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥350.09 | at 2020-06-30d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 38.1% | at 2024-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.9% | at 2023-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.2% | at 2022-06-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 37.8% | at 2021-06-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.5% | at 2020-06-30d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 6.7% | 2023-07-01 → 2024-06-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.3% | 2022-07-01 → 2023-06-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.1% | 2021-07-01 → 2022-06-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.4% | 2020-07-01 → 2021-06-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.9% | 2019-07-01 → 2020-06-30d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 22,147,494 | at 2024-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 21,925,104 | at 2023-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 21,925,104 | at 2022-06-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 21,789,724 | at 2021-06-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 21,789,724 | at 2020-06-30d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 93 | at 2024-06-30 | Standalone | Number of employees |
| Employees | 90 | at 2023-06-30 | Standalone | Number of employees |
| Employees | 71 | at 2022-06-30d | Standalone | Number of employees |
| Employees | 74 | at 2021-06-30d | Standalone | Number of employees |
| Employees | 73 | at 2020-06-30d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2023-07-01 → 2024-06-30 | ¥736m |
| Reconciling Itemsreconciling | depreciation | 2023-07-01 → 2024-06-30 | ¥683m |
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2024-06-30 | −¥3m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2024-06-30 | −¥3m |
| Reconciling Itemsreconciling | segment assets | at 2024-06-30 | ¥48.7bn |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2024-06-30 | −¥8.3bn |
| Medical Equipment Salesreportable segment | capex | 2023-07-01 → 2024-06-30 | ¥1.3bn |
| Medical Equipment Salesreportable segment | depreciation | 2023-07-01 → 2024-06-30 | ¥346m |
| Medical Equipment Salesreportable segment | employees | at 2024-06-30 | 1921 pure |
| Medical Equipment Salesreportable segment | revenue | 2023-07-01 → 2024-06-30 | ¥254.0bn |
| Medical Equipment Salesreportable segment | revenue external | 2023-07-01 → 2024-06-30 | ¥254.0bn |
| Medical Equipment Salesreportable segment | revenue intersegment | 2023-07-01 → 2024-06-30 | ¥3m |
| Medical Equipment Salesreportable segment | segment assets | at 2024-06-30 | ¥64.6bn |
| Medical Equipment Salesreportable segment | segment profit | 2023-07-01 → 2024-06-30 | ¥9.2bn |
| Nursing Welfarereportable segment | capex | 2023-07-01 → 2024-06-30 | ¥444m |
| Nursing Welfarereportable segment | depreciation | 2023-07-01 → 2024-06-30 | ¥503m |
| Nursing Welfarereportable segment | employees | at 2024-06-30 | 191 pure |
| Nursing Welfarereportable segment | revenue | 2023-07-01 → 2024-06-30 | ¥5.8bn |
| Nursing Welfarereportable segment | revenue external | 2023-07-01 → 2024-06-30 | ¥5.8bn |
| Nursing Welfarereportable segment | segment assets | at 2024-06-30 | ¥1.5bn |
| Nursing Welfarereportable segment | segment profit | 2023-07-01 → 2024-06-30 | ¥436m |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-07-01 → 2024-06-30 | ¥1.7bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-07-01 → 2024-06-30 | ¥849m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-07-01 → 2024-06-30 | ¥259.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-07-01 → 2024-06-30 | ¥259.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-07-01 → 2024-06-30 | ¥3m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-06-30 | ¥66.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-07-01 → 2024-06-30 | ¥9.6bn |
| Reconciling Itemsreconciling | capex | 2022-07-01 → 2023-06-30 | ¥407m |
| Reconciling Itemsreconciling | depreciation | 2022-07-01 → 2023-06-30 | ¥703m |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2023-06-30 | −¥240,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2023-06-30 | −¥240,000 |
| Reconciling Itemsreconciling | segment assets | at 2023-06-30 | ¥40.3bn |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2023-06-30 | −¥7.8bn |
| Medical Equipment Salesreportable segment | capex | 2022-07-01 → 2023-06-30 | ¥506m |
| Medical Equipment Salesreportable segment | depreciation | 2022-07-01 → 2023-06-30 | ¥312m |
| Medical Equipment Salesreportable segment | revenue | 2022-07-01 → 2023-06-30 | ¥233.6bn |
| Medical Equipment Salesreportable segment | revenue external | 2022-07-01 → 2023-06-30 | ¥233.6bn |
| Medical Equipment Salesreportable segment | revenue intersegment | 2022-07-01 → 2023-06-30 | ¥240,000 |
| Medical Equipment Salesreportable segment | segment assets | at 2023-06-30 | ¥55.8bn |
| Medical Equipment Salesreportable segment | segment profit | 2022-07-01 → 2023-06-30 | ¥9.3bn |
| Nursing Welfarereportable segment | capex | 2022-07-01 → 2023-06-30 | ¥479m |
| Nursing Welfarereportable segment | depreciation | 2022-07-01 → 2023-06-30 | ¥463m |
| Nursing Welfarereportable segment | revenue | 2022-07-01 → 2023-06-30 | ¥5.5bn |
| Nursing Welfarereportable segment | revenue external | 2022-07-01 → 2023-06-30 | ¥5.5bn |
| Nursing Welfarereportable segment | segment assets | at 2023-06-30 | ¥1.4bn |
| Nursing Welfarereportable segment | segment profit | 2022-07-01 → 2023-06-30 | ¥405m |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-07-01 → 2023-06-30 | ¥985m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-07-01 → 2023-06-30 | ¥774m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-07-01 → 2023-06-30 | ¥239.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-07-01 → 2023-06-30 | ¥239.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-07-01 → 2023-06-30 | ¥240,000 |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-06-30 | ¥57.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-07-01 → 2023-06-30 | ¥9.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,593
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任監査法人トーマツ | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)石 黒 宏 和 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)望 月 邦 彦 | |
| Key audit matters consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)旧株式会社アクティブメディカルに係るのれんの評価 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Reference kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)連結財務諸表の【注記事項】（重要な会計上の見積り）のれんの評価 | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row2Member | Original text (Japanese)株式会社田中医科器械製作所に係るのれんの評価 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Reference kam consolidated | FilingDateInstant_Row2Member | Original text (Japanese)連結財務諸表の【注記事項】（重要な会計上の見積り）のれんの評価 | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Other information consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information consolidated (text) | FilingDateInstant | Text · Plus | |
| Independent auditors report non consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)有限責任監査法人トーマツ | |
| Cpa1 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)石 黒 宏 和 | |
| Cpa2 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)望 月 邦 彦 | |
| Key audit matters non consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam non consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)子会社株式の評価 | |
| Description including reason kam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Reference kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)【注記事項】（有価証券関係） | |
| Auditors response kam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior4YearDuration | 210388116000 | JPY |
| Net sales (5-year summary) | Prior3YearDuration | 213329593000 | JPY |
| Net sales (5-year summary) | Prior2YearDuration | 226606414000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 239054420000 | JPY |
| Net sales (5-year summary) | CurrentYearDuration | 259789000000 | JPY |
| Ordinary income loss (5-year summary) | Prior4YearDuration | 1598332000 | JPY |
| Ordinary income loss (5-year summary) | Prior3YearDuration | 3176970000 | JPY |
| Ordinary income loss (5-year summary) | Prior2YearDuration | 2757877000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 2423616000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYearDuration | 1750486000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior4YearDuration | 951357000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior3YearDuration | 2065996000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior2YearDuration | 1867916000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 1498008000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYearDuration | 1124676000 | JPY |
| Comprehensive income (5-year summary) | Prior4YearDuration | 1493593000 | JPY |
| Comprehensive income (5-year summary) | Prior3YearDuration | 2275012000 | JPY |
| Comprehensive income (5-year summary) | Prior2YearDuration | 1803176000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 1680863000 | JPY |
| Comprehensive income (5-year summary) | CurrentYearDuration | 1474890000 | JPY |
| Net assets (5-year summary) | Prior4YearInstant | 13873183000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |